221 related articles for article (PubMed ID: 9925541)
1. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.
Petit C; Yardley V; Gaboriau F; Bolard J; Croft SL
Antimicrob Agents Chemother; 1999 Feb; 43(2):390-2. PubMed ID: 9925541
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
3. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani.
Mbongo N; Loiseau PM; Craciunescu DG; Robert-Gero M
Acta Trop; 1998 Jun; 70(2):239-45. PubMed ID: 9698271
[No Abstract] [Full Text] [Related]
6. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
7. Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.
Mohamed-Ahmed AH; Seifert K; Yardley V; Burrell-Saward H; Brocchini S; Croft SL
Antimicrob Agents Chemother; 2013 Oct; 57(10):4608-14. PubMed ID: 23796924
[TBL] [Abstract][Full Text] [Related]
8. Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo.
Kar A; Jayaraman A; Charan Raja MR; Srinivasan S; Debnath J; Mahapatra SK
Int Immunopharmacol; 2021 Feb; 91():107291. PubMed ID: 33360084
[TBL] [Abstract][Full Text] [Related]
9. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.
Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S
Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612
[TBL] [Abstract][Full Text] [Related]
10. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
Larabi M; Yardley V; Loiseau PM; Appel M; Legrand P; Gulik A; Bories C; Croft SL; Barratt G
Antimicrob Agents Chemother; 2003 Dec; 47(12):3774-9. PubMed ID: 14638481
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
[TBL] [Abstract][Full Text] [Related]
14. Lupeol and amphotericin B mediate synergistic anti-leishmanial immunomodulatory effects in Leishmania donovani-infected BALB/c mice.
Das A; Jawed JJ; Das MC; Parveen S; Ghosh C; Majumdar S; Saha B; Bhattacharjee S
Cytokine; 2021 Jan; 137():155319. PubMed ID: 33002744
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
Croft SL; Davidson RN; Thornton EA
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
20. Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.
Loiseau PM; Imbertie L; Bories C; Betbeder D; De Miguel I
Antimicrob Agents Chemother; 2002 May; 46(5):1597-601. PubMed ID: 11959611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
